Evidence map›Paper›PMID 40277436›Full record

ArticleVirulence2025

A promising endeavor against human cytomegalovirus: Predominant epitopes-based recombinant subunit vaccine RH

Zonghui Li, Shasha Jiang, Wenxuan Liu, Xiaoli Yang, Fengjun Liu, Xu Li, Jun Li, Meng Yu, Zhun Wei, Bin Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Cytomegalovirus Vaccines in Transplantation: History, Hurdles, and Hope.Transplant infectious disease : an official journal of the Transplantation Society · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zonghui LiDepartment of Pathogenic Biology, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao, China.ORCID 0009-0001-7593-5279
Shasha JiangDepartment of Pathogenic Biology, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao, China.ORCID 0000-0003-1102-6401
Wenxuan LiuDepartment of Pathogenic Biology, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao, China.
Xiaoli YangDepartment of Pathogenic Biology, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao, China.
Fengjun LiuDepartment of Pathogenic Biology, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao, China.
Xu LiDepartment of Pathogenic Biology, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao, China.
Jun LiDepartment of Pathogenic Biology, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao, China.
Meng YuDepartment of Pathogenic Biology, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao, China.
Zhun WeiDepartment of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China.
Bin WangDepartment of Pathogenic Biology, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao, China.ORCID 0000-0002-8708-036X
Dongmeng QianDepartment of Pathogenic Biology, Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao, China.ORCID 0009-0009-1074-1607

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is widespread in the population, typically remaining latent. However, it can cause severe morbidity and mortality in transplant patients and immunodeficient individuals. Currently, there is no approved vaccine against HCMV. This study used immunoinformatics methods to predict the predominant T and B-cell epitopes of three key HCMV proteins, including phosphoprotein 65 (pp65), pp150, and immediate-early protein 1 (IE1). Subsequently, we synthesized a recombinant subunit vaccine (RH

Indexed as

CytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocytePhosphoproteinsViral Matrix ProteinsAnimalsAntibodies, ViralFemaleHumansImmediate-Early ProteinsImmunogenicity, VaccineMiceMice, Inbred BALB CVaccines, SubunitAntibodies, Viralcytomegalovirus matrix protein 65kDaCytomegalovirus VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteIE1 protein, cytomegalovirusImmediate-Early ProteinsPhosphoproteinsVaccines, SubunitVaccines, SyntheticViral Matrix ProteinsCytomegalovirusimmunogenicitypredominant epitopesrecombinant subunit vaccinesignaling pathway

Identifiers

PMID40277436
PMCPMC12064061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.